Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study

Autor: Chibaudel, Benoist, André, Thierry, Tournigand, Christophe, Louvet, Christophe, Benetkiewicz, Magdalena, Larsen, Annette K., de Gramont, Aimery

Publikováno v: In Clinical Colorectal Cancer September 2020 19(3):200-208

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study

Autor: Christophe Tournigand, Benoist Chibaudel, Thierry André, Magdalena Benetkiewicz, Annette K. Larsen, Christophe Louvet, Aimery de Gramont

Publikováno v: Clinical Colorectal Cancer
Clinical Colorectal Cancer, 2020, 19, pp.200-208.e1. ⟨10.1016/j.clcc.2020.02.012⟩
Clinical Colorectal Cancer, Elsevier, 2020, 19, pp.200-208.e1. ⟨10.1016/j.clcc.2020.02.012⟩

International audience; Introduction: We evaluated the prognostic value of KRAS and primary tumor location (PTL) for overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) in metastatic colorectal cancer (mCRC).Ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d02520b7d02a4cdba0a5a199762da6d
https://hal.science/hal-03492386/document

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial

Autor: Gérard Lledo, Benoit Samson, Dewi Vernerey, Marie-Line Garcia-Larnicol, Olivier Dupuis, Ghaouti Nabil Baba Hamed, Werner Scheithauer, May Mabro, Ahmed Khalil, Nicole Tubiana-Mathieu, Nathalie Aucoin, Jérôme Dauba, Frédéric Viret, Aimery de Gramont, Thierry André, Christophe Tournigand, Benoist Chibaudel, Yves Rinaldi, Elisabeth Carola, Christophe Louvet

Publikováno v: Journal of Clinical Oncology. 36:737-737

737 Background: Primary tumor sidedness (PTS) could be a predictive maker for treatment efficacy of EGFR inhibitors monoclonal antibodies in patients with wild-type (WT) RAS metastatic colorectal cancer (MCRC), cetuximab having limited efficacy in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2b6084e1a8f7d295a7796bdc3fce8c1
https://doi.org/10.1200/jco.2018.36.4_suppl.737

PD-010 Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in CRC models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial

Autor: Mésange, P., Bouygues, A., Muller, D., Savina, A., Chibaudel, B., Tournigand, C., André, T., de Gramont, A., Larsen, A.

Publikováno v: In Annals of Oncology June 2015 26 Supplement 4:iv103-iv103

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.